AwardsCertificate of Merit
1. Discuss the novel role of programmed cell death 1 (PD1) inhibitors in current cancer therapy, and understand their pharmacologic mechanisms.
2. Recognize the imaging manifestations of PD1 inhibitor immune-related adverse events across a variety of organ systems.
3. Case-based approach to PD1 inhibitor immune-related imaging findings.
PD1 inhibition – novel role in cancer therapy Pharmacologic mechanisms of PD1 inhibition FDA-approved use in cancer subtypes and emerging applications Immune-related adverse events and their treatmentImaging manifestations of PD1 inhibitor immune-related adverse events Hypophysitis – enlargement and abnormal MRI signal with clinical hypopituitarism Thyroiditis – heterogeneous enhancement and atrophy with clinical hypothyroidism Organizing Pneumonia – airspace consolidations and ground-glass attenuation ARDS – diffuse ground-glass attenuation and consolidations Pleuritis – progressive diffuse pleural thickening with pathologic correlation Pancreatitis – diffuse hypermetabolism on FDG PET/CT Nephritis – geographic hypoenhancing renal lesions Mesenteritis – soft tissue masses, lymphadenopathy and fat stranding with pathologic correlation Colitis – colonic wall thickening and fat strandingConclusion Consider immune-related adverse events in patients on PD1 therapy